Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Long-acting anti-inflammatory injectable DEX-Gel with sustained release and self-healing properties regulates TH1/TH2 immune balance for minimally invasive treatment of allergic rhinitis

Fig. 2

DEX-Gel has superior biocompatibility. A Viability of the L929 cells in different concentrations of DEX-Gel extract for 24, 48, and 72 h (n = 3). B The hemolysis ratio in different concentrations of DEX-Gel extraction、PBS (−) and distilled water ( +) (n = 3). C The body weight of rats in different groups (n = 5). D Morphology and oscillation duration of the maxillary mucosa (red marker area) of Bufo chinensis in different concentrations of DEX-Gel extracts. a PBS, bf 6.25%, 12.5%, 25%, 50%, and 100% concentration of DEX-Gel extract. E, F Photographs of HE staining and IL4 levels in the nasal mucosa. Arrows point to inflammatory cells (n = 3). G HE staining Photographs of major organs. Scare bars = 200 µm in (D); Scare bars = 50 µm in (E); Scare bars = 250 µm in (G). Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001, significantly different from the ANOVA group

Back to article page